首页> Blood advances> Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Katharine L,Lewis

第一单位： Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.;Linear Clinical Research, Nedlands, Australia.

作者： Katharine L,Lewis ^[1] ; Sarit E,Assouline ^[2] ; Ross,Baker ^[3] ; Nancy L,Bartlett ^[4] ; Dima,El-Sharkawi ^[5] ; Pratyush,Giri ^[6] ; Matthew,Ku ^[7] ; Matthew,Matasar ^[8] ; Stephen,Schuster ^[9] ; John,Radford ^[10] ; Michael C,Wei ^[11] ; Shen,Yin ^[11] ; Antonia,Kwan ^[11] ; Iris,To ^[11] ; Vibha,Raghavan ^[11] ; Lihua E,Budde ^[12] ; Chan Y,Cheah ^[1]

作者单位： Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.;Linear Clinical Research, Nedlands, Australia. ^[1] Division of Hematology, Jewish General Hospital, Montreal, Canada. ^[2] Perth Blood Institute, Perth, Australia. ^[3] Division of Oncology, Washington University School of Medicine, St. Louis, MO. ^[4] Department of Haematology, The Royal Marsden Hospital, London, United Kingdom. ^[5] Department of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia. ^[6] Department of Haematology, St Vincent's Hospital and The University of Melbourne, Melbourne, Australia. ^[7] Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ. ^[8] Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. ^[9] Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. ^[10] Genentech Inc, San Francisco, CA. ^[11] Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA. ^[12]

医学主题词人类(Humans);女(雌)性(Female);中年人(Middle Aged);老年人(Aged);男(雄)性(Male);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);成年人(Adult);复发(Recurrence);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);治疗结果(Treatment Outcome);细胞转化, 肿瘤(Cell Transformation, Neoplastic)

DOI 10.1182/bloodadvances.2025017914

PMID 41643182

发布时间 2026-06-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Blood advances

2026年10卷9期

3011-3019页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

Blood advances

2026年10卷9期

3011-3019页

检索历史清除

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除